Good
Mostly Aligned
Patient Risk:
Low
Summary
Two claims match the label excerpts (brand/active ingredient and indication/route type), while the company/marketing attribution is not supported by the provided prescribing information excerpts.
Category Scores
Accurate Statements
Orgovyx is the brand name for relugolix.
Label text identifies ORGOVYX active ingredient as relugolix (Drug / Active ingredient(s) and multiple sections referencing relugolix).
Relugolix is an oral androgen-deprivation therapy used in prostate cancer.
Indications: “ORGOVYX is indicated for the treatment of adult patients with advanced prostate cancer.” Dosage form is oral tablets and mechanism describes reducing testosterone via GnRH receptor antagonism.
Unsupported Statements
Myovant Sciences is the company associated with the commercialization/marketing of Orgovyx.
No information about the commercial/marketing company is present in the provided FDA label excerpts.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The unsupported claim concerns marketing/commercialization attribution and does not affect dosing, contraindications, or safety-critical use based on the provided excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Marketing/commercialization company attribution is unsupported by the provided label excerpts.
Suggested Improvement
Remove or qualify the company/marketing attribution unless supported by the FDA label text provided.